Structural Heart Symposium: Mastery in Mitral Valve and Tricuspid Valve Therapies
Register yourself and members of your heart team for the Structural Heart Symposium, where attendees will develop new minimally invasive and transcatheter skills, explore upcoming technologies, and stay relevant in the rapidly changing field of mitral and tricuspid valve therapy. Register by June 21 to receive the early bird discount.
Provide your contact information to receive updates about the event.
The demand for new transcatheter technologies to treat mitral and tricuspid valve diseases continues to grow at a remarkable pace. Originally designed for high-risk patients, these therapies are now being used in lower-risk populations. This course is designed to help ensure that cardiothoracic surgeons and other members of the heart team possess the appropriate knowledge and technical skills to safely and effectively perform transcatheter mitral valve replacement (TMVR), transcatheter tricuspid valve replacement, and other newer procedures.
The Symposium will feature didactic sessions, case-based presentations, and hands-on demonstrations of the latest devices by a distinguished multidisciplinary faculty that include pioneers in the treatment of structural heart disease.
Gorav Ailawadi, MD, MBA, Ann Arbor, MI
Tsuyoshi Kaneko, MD, Boston, MA
Molly A. Szerlip, MD, Plano, TX
Vinod H. Thourani, MD, Atlanta, GA
After participating in this educational activity, participants should be able to:
- Outline the decision-making process for the management of structural heart disease and the heart team approach to delivery of care
- Identify ways to treat severe mitral regurgitation, including novel transcatheter approaches and devices
- Explain the patient selection approach and techniques for tricuspid valve repair, including novel transcatheter approaches
(Through June 21)
(June 22 - August 19)
|STS Physician Member||$900||$1,000|
|STS Associate, Resident/Fellow, and Medical Student Members||$300||$400|
|Non-Member Allied Health, Residents, Medical Students||$400||$500|
*An STS Member ID (6 digits) is required to receive the discounted member rate. Database participation is not the same as STS membership. A Database participant ID is different from an STS Member ID. For help with an STS Member ID, contact Member Services.
A block of rooms for Symposium attendees has been reserved at the Fairmont Chicago Millennium Park (200 North Columbus Drive, Chicago, IL 60601), where the meeting will take place. The special group rate is $209 (single/double), $239 (triple), or $269 (quad), plus state and local taxes. This rate is available until Friday, July 29, on a first-come, first-served basis. There are two ways to reserve a room in the STS block:
- Make your reservation online.
- Call 866-540-4408 and reference “Structural Heart Symposium.”
STS requires that all professional registrants, faculty, exhibitors, guests, and STS staff be fully vaccinated against COVID-19 prior to their attendance. Attendees are considered fully vaccinated 2 weeks after the second dose in a two-dose series, or 2 weeks after a single-dose vaccine; and, if eligible, have received a booster shot.
STS has partnered with 42Chat/HealthShield, a third-party SMS texting-based service that will manage the collection of vaccine documentation. You will need to provide a telephone number through which you can be reached by SMS texting. Attendees will receive an invitation with instructions on how to upload their proof of vaccination in late July.
The Society of Thoracic Surgeons is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
The Society of Thoracic Surgeons designates this live activity for a maximum of 14.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physician Assistants (PAs) may claim AMA PRA Category 1 Credits™ for completing this activity.
Ethical MedTech Compliance:
This symposium has been assessed by Ethical MedTech and is PROVISIONALLY COMPLIANT with the MedTech Europe Code of Ethical Business Practice.